From Health Affairs Today <[email protected]>
Subject Federal Funding & Costly HIV Drugs
Date May 25, 2023 8:05 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
Save $40 on a new Insider membership!
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌


Problems viewing this email?

View Message In Browser
<[link removed]>

Thursday, May 25, 2023 | The Latest Research, Commentary, And News From
Health Affairs

Dear John,

Join us and Carrie Colla, director of health analysis at CBO, for a free
<[link removed]>Policy
Spotlight Event
<[link removed]>
on June 1. This event is open to all.

Register
<[link removed]>


HIV Drug Development & Costs

In the May issue
<[link removed]>,
Frazer Tessema and colleagues conduct a precise accounting of government
funding
<[link removed]>
that directly contributed to the discovery and development of the first
HIV pre-exposure prophylaxis medication, tenofovir disoproxil
fumarate-emtricitabine (TDF-FTC).

The authors determine that government funding for TDF-FTC included $143
million in (inflation-adjusted) direct funding from the National
Institutes of Health and an additional $314 million in "potentially
related awards."

These findings lead to questions about whether high prices for the drug
were justified, given the extent of taxpayer contribution to its
development.

"By 2019 TDF-FTC had a list price of $1,600-$2,000 per month in the
US but less than $6 in Australia. It was generically available in many
other high-income countries besides the US by 2019, despite the CDC's
patents," Tessema and colleagues point out.

Read More
<[link removed]>


 

[link removed]


Elsewhere At Health Affairs

Today in Forefront, David Muhlestein discusses how the new pool of
commercial insurer price data isincredibly rich and offers many
opportunities
<[link removed]>,
but poses some significant challenges related to the size, complexity,
and quality.

This article is the latest in the Health Affairs Forefront series,
Provider Prices in the Commercial Sector
<[link removed]>.

Another article in the series was released today, Yang Wang and
colleagues argue how to analyze and improve the usability of insurer
price transparency data
<[link removed]>.

Finally, in our Accountable Care for Population Health
<[link removed]>
series, Joshua Liao and Amol Navathe write about advanced payments in
population-based models
<[link removed]>
to address equity.

[link removed]


Daily Digest

Using Advanced Payments In Population-Based Models To Address Equity
<[link removed]>

Joshua Liao and Amol Navathe

Commercial Insurer Price Transparency: A Comparison of Four National
Payers
<[link removed]>
David Muhlestein

How To Analyze and Improve the Usability of Insurer Price Transparency
<[link removed]>
Yang Wang et al.

Federal Funding For Discovery and Development of Costly HIV Drugs Was
Far More Than Previously Estimated
<[link removed]>
Frazer Tessema et al.

 

[link removed]


During May, we're highlighting influential Asian American, Native
Hawaiian, and Pacific Islander voices and organizations who have made an
impact on health equity and policy.

In a May 2023 Forefront article, Y. Tony Yang and coauthors provide a
synthesis of why international recruitment alone will not solve the
latest US nursing staffing crisis, and provide several federal-level
policy solutions that could be implemented
<[link removed]>."

 

[link removed]


Health Affairs is launching a contest! The premise is simple. Finish the
statement "You're A Health Policy Wonk If..."

We'll share some of the submissions on Forefront in July, and the
first-place winner of the contest will receive a Health Affairs tumbler
and a free Unlimited membership
<[link removed]>
for a year. Submit by May 31
<[link removed]>.


[link removed]

[link removed]

 

[link removed]

 

[link removed]

 

[link removed]

 

[link removed]

 

mailto:[email protected]

About Health Affairs

Health Affairs is the leading peer-reviewed journal
<[link removed]> at the intersection of health,
health care, and policy. Published monthly by Project HOPE, the journal
is available in print and online. Late-breaking content is also found
through healthaffairs.org <healthaffairs.org>, Health Affairs Today
<[link removed]>, and Health Affairs Sunday
Update <[link removed]>.  

Project HOPE <[link removed]> is a global health and
humanitarian relief organization that places power in the hands of local
health care workers to save lives across the globe. Project HOPE has
published Health Affairs since 1981.

Copyright © Project HOPE: The People-to-People Health Foundation, Inc.

Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States

Privacy Policy <[link removed]>

To unsubscribe from this email, update your email preferences here
<[link removed]>.
_________________

Sent to [email protected]

Unsubscribe:
[link removed]

Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States
Screenshot of the email generated on import

Message Analysis